These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15680235)

  • 1. The SH2 domain: versatile signaling module and pharmaceutical target.
    Machida K; Mayer BJ
    Biochim Biophys Acta; 2005 Feb; 1747(1):1-25. PubMed ID: 15680235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase.
    Dombrosky-Ferlan PM; Corey SJ
    Oncogene; 1997 May; 14(17):2019-24. PubMed ID: 9160881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70.
    García-Echeverria C
    Curr Med Chem; 2001 Nov; 8(13):1589-604. PubMed ID: 11562287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The signal transduction through Grb2/Ash in hematopoietic cells.
    Odai H; Hanazono Y; Sasaki K; Iwamatu A; Yazaki Y; Hirai H
    Leukemia; 1997 Apr; 11 Suppl 3():405-7. PubMed ID: 9209406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
    Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
    J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
    Bradshaw JM; Mitaxov V; Waksman G
    J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine-phosphorylated Cbl binds to Crk after T cell activation.
    Sawasdikosol S; Chang JH; Pratt JC; Wolf G; Shoelson SE; Burakoff SJ
    J Immunol; 1996 Jul; 157(1):110-6. PubMed ID: 8683103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains.
    Chalupny NJ; Aruffo A; Esselstyn JM; Chan PY; Bajorath J; Blake J; Gilliland LK; Ledbetter JA; Tepper MA
    Eur J Immunol; 1995 Oct; 25(10):2978-84. PubMed ID: 7589101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of Src-like adaptor protein 2 reveals close association of SH3 and SH2 domains through β-sheet formation.
    Wybenga-Groot LE; McGlade CJ
    Cell Signal; 2013 Dec; 25(12):2702-8. PubMed ID: 24018043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase.
    Meng W; Sawasdikosol S; Burakoff SJ; Eck MJ
    Nature; 1999 Mar; 398(6722):84-90. PubMed ID: 10078535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.
    Vu CB
    Curr Med Chem; 2000 Oct; 7(10):1081-100. PubMed ID: 10911019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
    Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
    J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor.
    Miyoshi-Akiyama T; Aleman LM; Smith JM; Adler CE; Mayer BJ
    Oncogene; 2001 Jul; 20(30):4058-69. PubMed ID: 11494134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in structural dynamics of the Grb2 adaptor protein upon binding of phosphotyrosine ligand to its SH2 domain.
    de Mol NJ; Catalina MI; Fischer MJ; Broutin I; Maier CS; Heck AJ
    Biochim Biophys Acta; 2004 Jul; 1700(1):53-64. PubMed ID: 15210125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SH2 and SH3 domains as targets for anti-proliferative agents.
    Vidal M; Gigoux V; Garbay C
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):175-86. PubMed ID: 11682324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBL-GRB2 interaction in myeloid immunoreceptor tyrosine activation motif signaling.
    Park RK; Kyono WT; Liu Y; Durden DL
    J Immunol; 1998 May; 160(10):5018-27. PubMed ID: 9590251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
    Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
    J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
    Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
    Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity IgG receptor activation of Src family kinases is required for modulation of the Shc-Grb2-Sos complex and the downstream activation of the nicotinamide adenine dinucleotide phosphate (reduced) oxidase.
    Park RK; Erdreich-Epstein A; Liu M; Izadi KD; Durden DL
    J Immunol; 1999 Dec; 163(11):6023-34. PubMed ID: 10570290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.